Sugi Predict

Sugi Predict / Compounds / SCHEMBL1047730

SCHEMBL1047730

SCHEMBL1047730

CCCS(=O)(=O)c1ccccc1Nc1cc2cc[nH]c(=O)c2c(Nc2ccc(N3CCOCC3)cc2)n1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ZAP70 P43403 10/20 0.67
▸ MAP4K1 Q92918 1/20 0.42
▸ JAK2 O60674 3/20 0.41
▸ SYK P43405 1/20 0.40
▸ TTK P33981 1/20 0.40
▸ TTBK1 Q5TCY1 1/20 0.39
▸ TTBK2 Q6IQ55 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ JAK1 P23458 1/20 0.39
▸ TYK2 P29597 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ MAPK10 P53779 1/20 0.39
▸ IGF1R P08069 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1049000 0.90 ZAP70 (0.73) ZAP70MAP4K1JAK2SYKTTK
SCHEMBL1045837 0.89 ZAP70 (0.67) ZAP70MAP4K1JAK2SYKTTK
SCHEMBL1049400 0.88 ZAP70 (0.70) ZAP70MAP4K1JAK2SYKTTK
SCHEMBL1047387 0.88 ZAP70 (0.77) ZAP70MAP4K1JAK2SYKTTK
SCHEMBL1047728 0.87 ZAP70 (0.69) ZAP70MAP4K1JAK2SYKTTK
SCHEMBL1044892 0.87 ZAP70 (0.69) ZAP70MAP4K1JAK2SYKTTK
SCHEMBL1047800 0.86 ZAP70 (0.67) ZAP70MAP4K1JAK2SYKTTK
SCHEMBL1049428 0.82 ZAP70 (0.66) ZAP70MAPK10IGF1R
SCHEMBL1048240 0.81 ZAP70 (0.67) ZAP70MAPK10
SCHEMBL1048073 0.81 ZAP70 (0.44) ZAP70JAK2SYKJAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 — — US claimed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 — — US claimed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 — — EP claimed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 — — WO claimed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 — — US disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 — — US disclosed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 — — EP disclosed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FYN, SYK, RET ZAP70 4/4885MAP4K1 254/4885JAK2 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.